BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Cuts Target Price to $9

Moomoo NewsNov 29 06:32 ET · Ratings

Outlook Therapeutics Price Target Lowered to $9 From $50 at BTIG

TipRanksNov 29 05:50 ET

Outlook Therapeutics Analyst Ratings

BenzingaNov 29 04:48 ET · Ratings

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)

TipRanksNov 28 09:40 ET · Ratings

H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsNov 28 09:32 ET · Ratings

Outlook Therapeutics, Inc. (NASDAQ:OTLK): Is Breakeven Near?

Simply Wall StNov 28 08:23 ET